Paper Details

  1. Home
  2. Paper Details

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Author: ArcadiMaria Teresa, BeltramiGermana, BocchiaMonica, BovaIrene, BrecciaMassimo, BuccisanoFrancesco, CandoniAnna, CapodannoIsabella, CascavillaNicola, CastelliAndrea, CrisàElena, CufariPatrizia, D'ErrigoMaria Grazia, DelfinoIlaria Maria, Di RenzoNicola, FattizzoBruno, FenauxPierre, FerreroDario, GermingUlrich, GiaiValentina, GuariniAttilio, IannìGiuseppe, ImperaStefana, LatagliataRoberto, LiberatiAnna Marina, MolteniAlfredo, NiscolaPasquale, OlivaEsther Natalie, PalumboGiuseppe A, PatriarcaAndrea, PoloniAntonella, RedaGianluigi, RiccoAlessandra, RivaMarta, RivelliniFlavia, RizzoLorenzo, RussoEmilio, SalutariPrassede, SantiniValeria, Stamatoullas-BastardAspasia, TripepiGiovanni, ZiniGina

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Eltrombopag was effective and relatively safe in patients with low-risk myelodysplastic syndromes (MDS) and severe thrombocytopenia. In a randomized, placebo-controlled trial of 169 patients, platelet response (PLT-R) occurred in 42.3% of eltrombopag patients versus 11.1% in placebo patients.
Paper Details　
Original Abstract of the Article :
PURPOSE: In myelodysplastic syndromes (MDS), severe thrombocytopenia is associated with poor prognosis. This multicenter trial presents the second-part long-term efficacy and safety results of eltrombopag in patients with low-risk MDS and severe thrombocytopenia. METHODS: In this single-blind, rand...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552995/

データ提供：米国国立医学図書館（NLM）

Eltrombopag for Low-Risk Myelodysplastic Syndromes with Thrombocytopenia: A Promising Treatment Approach

Myelodysplastic syndromes (MDS) are a group of blood disorders characterized by the production of abnormal blood cells. Thrombocytopenia, a low platelet count, is a common complication of MDS and is associated with a poor prognosis. This multicenter trial explores the efficacy and safety of eltrombopag, a medication that stimulates platelet production, in patients with low-risk MDS and severe thrombocytopenia. The trial's findings indicate that eltrombopag is an effective and relatively safe treatment for improving platelet counts in these patients.

Eltrombopag: A Potential Game-Changer for Low-Risk MDS with Thrombocytopenia

The trial results demonstrate the effectiveness of eltrombopag in improving platelet counts in patients with low-risk MDS and severe thrombocytopenia. This medication showed a significant increase in platelet counts compared to placebo, suggesting its potential to improve clinical outcomes and quality of life for these patients.

Hope for MDS Patients: Improving Platelet Counts and Prognosis

This multicenter trial provides valuable information for patients with low-risk MDS and severe thrombocytopenia. The study's findings highlight the potential benefits of eltrombopag for improving platelet counts and potentially improving overall prognosis. This research underscores the need for continued investigation into effective treatment options for MDS.

Dr. Camel's Conclusion

Myelodysplastic syndromes are like the shifting sands of the desert, presenting a complex challenge for patients. Eltrombopag, like a sturdy camel, offers a reliable and effective means to navigate these challenging conditions. This research provides a hopeful perspective on the treatment of low-risk MDS with thrombocytopenia, offering new possibilities for improving patient outcomes and quality of life.
Date :
  1. Date Completed 2023-10-07
  2. Date Revised 2023-10-24
Further Info :

Pubmed ID

37294914

DOI: Digital Object Identifier

PMC10552995

Related Literature

Article Analysis
・Effects of eltrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.